Response to “Comment on cognitive function in the context of pharmacogenetic CYP2D6 variability and anticholinergic burden in older adults – results from the ActiFE study”
European Journal of Clinical Pharmacology · 2026
DOI: 10.1007/s00228-026-04183-8 ↗Kurz gefasst
Leserbrief in der Zeitschrift European Journal of Clinical Pharmacology, 2026. Verfasst von Linda Lorenz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Cholinergic Antagonists, Cognition. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum RWTH Aachen.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
We clarify that our analyses were exploratory and hypothesis-generating, with systematic stratification across CYP2D6 metaboliser groups rather than selection based on an interaction p < 0.2 threshold. A post-hoc Benjamini–Hochberg sensitivity analysis provided supportive, but not confirmatory, evidence for the hypothesised stronger association between anticholinergic burden and cognitive function among individuals with reduced CYP2D6 activity. Given the limited subgroup sizes, ceiling effects, and generally high cognitive performance of the cohort, these findings should be considered hypothesis-generating.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, Germany.
- Institute for Geriatric Research, Ulm University Medical Centre, Ulm, Germany.
- Geriatric Centre Ulm at AGAPLESION Bethesda Hospital, Ulm, Germany.
- Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
- Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.
- Institute of Clinical Pharmacology, University Hospital RWTH Aachen, Aachen, Germany. kjust@ukaachen.de.
Förderung
- Universitätsklinikum RWTH Aachen
Zitieren
APA
Lorenz, L., Berres, J., Denkinger, M. D., Rothenbacher, D., Braig, S., Dallmeier, D., & Just, K. S. (2026). Response to “Comment on cognitive function in the context of pharmacogenetic CYP2D6 variability and anticholinergic burden in older adults – results from the ActiFE study”. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-026-04183-8
Vancouver
Lorenz L, Berres J, Denkinger MD, Rothenbacher D, Braig S, Dallmeier D, et al. Response to “Comment on cognitive function in the context of pharmacogenetic CYP2D6 variability and anticholinergic burden in older adults – results from the ActiFE study”. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-026-04183-8
BibTeX
@article{Lorenz2026,
author = {Lorenz, Linda and Berres, Judith and Denkinger, Michael D and Rothenbacher, Dietrich and Braig, Stefanie and Dallmeier, Dhayana and Just, Katja S},
title = {Response to “Comment on cognitive function in the context of pharmacogenetic CYP2D6 variability and anticholinergic burden in older adults – results from the ActiFE study”},
journal = {European Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1007/s00228-026-04183-8}
}
EUVIMED